The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โABBVโ.
According to AbbVie's latest financial reports the company has $10.39 B in net assets.
A companyโs net assets is the sum of its assets minus the sum of its liabilities.
Year | Net assets | Change |
---|---|---|
2023-12-31 | $10.39 B | -39.86% |
2022-12-31 | $17.28 B | 11.99% |
2021-12-31 | $15.43 B | 17.86% |
2020-12-31 | $13.09 B | -260.27% |
2019-12-31 | $-8.18 B | -3.24% |
2018-12-31 | $-8.45 B | -265.71% |
2017-12-31 | $5.09 B | 9.94% |
2016-12-31 | $4.63 B | 17.52% |
2015-12-31 | $3.94 B | 126.46% |
2014-12-31 | $1.74 B | -61.22% |
2013-12-31 | $4.49 B | 33.57% |
2012-12-31 | $3.36 B | -71.82% |
2011-12-31 | $11.93 B | -24.01% |
2010-12-31 | $15.70 B |
Company | Net assets | differencediff. | Country |
---|---|---|---|
Pfizer PFE | $89.28 B | 758.79% | ๐บ๐ธ USA |
Eli Lilly LLY | $10.86 B | 4.49% | ๐บ๐ธ USA |
Amgen AMGN | $6.23 B | -40.06% | ๐บ๐ธ USA |
Biogen BIIB | $14.79 B | 42.34% | ๐บ๐ธ USA |
Gilead Sciences GILD | $22.74 B | 118.80% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $29.48 B | 183.59% | ๐บ๐ธ USA |
AstraZeneca AZN | $39.16 B | 276.70% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $16.28 B | 56.66% | ๐ฌ๐ง UK |
Neurocrine Biosciences
NBIX | $2.23 B | -78.53% | ๐บ๐ธ USA |